<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01523574</url>
  </required_header>
  <id_info>
    <org_study_id>VE01</org_study_id>
    <nct_id>NCT01523574</nct_id>
  </id_info>
  <brief_title>Vitamin E for Oxaliplatin-induced Peripheral Neuropathy Prophylaxis</brief_title>
  <official_title>Randomized, Placebo Controlled Study of Vitamin E for Oxaliplatin-induced Neuropathy Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Felipe Melo Cruz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faculdade de Medicina do ABC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Oxaliplatin (Ox) is a frequently used platinum-based medication that is a part
      of many chemotherapy regimens for the treatment of several gastrointestinal malignancies. One
      of the most important limitations to its use is the induction of both acute and chronic
      peripheral neuropathy (PN). Previous studies have shown that vitamin E can reduce the
      incidence of cisplatin-induced PN by 50%. In this study, the investigators aimed to determine
      if vitamin E could also prevent Ox-induced acute PN
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a prospective, phase II, randomized pilot study. Patients were randomized 5 days
      before the start of Ox to receive either vitamin E at 400 mg daily or placebo, until after
      the end of the Ox-based chemotherapy regimen. The investigators evaluated PN intensity using
      the CTCAE version 3 and specific Ox PN gradation scales. The investigators included patients
      with colorectal and gastric cancers scheduled to receive Ox-based chemotherapy. Both groups
      received calcium and magnesium supplements before and after oxaliplatin infusions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and grade of Peripheral neuropathy by common terminology criteria for adverse events v 3.0(CTCAE)and specific Ox PN gradation scales.</measure>
    <time_frame>Within the first 45 days (plus or minus 7 days) of treatment ( 3 x oxaliplatin infusions)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Five days before chemotherapy:1 x daily Used until one week after third oxaliplatin infusion: 1 x daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin e</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Five days before chemotherapy:1 x daily Used until one week after third oxaliplatin infusion: 1 x daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin E</intervention_name>
    <description>Vitamin E 400mg PO orally</description>
    <arm_group_label>Vitamin e</arm_group_label>
    <other_name>Calcium gluconate 1g, IV, before and after oxaliplatin</other_name>
    <other_name>Magnesium sulfate 1g, IV, before and after oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, given orally</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Calcium gluconate 1g, IV, before and after oxaliplatin</other_name>
    <other_name>Magnesium sulfate 1g, IV, before and after oxaliplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ECOG Performance status 0 or 1

          -  Older than 18 years

          -  New diagnose with colorectal or gastric cancer

          -  Scheduled to receive oxaliplatin-based regimens

        Exclusion Criteria:

          -  Excluded patients with a previous history of PN or with symptomatic PN at entry into
             the study

          -  Excluded patients who received other chemotherapy regimens (except isolated
             5-fluorouracil)

          -  Patients currently receiving gabapentin, carbamazepine, amitriptyline, amifostine or
             multivitamins
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Auro del Giglio, phD</last_name>
    <role>Study Director</role>
    <affiliation>Faculdade de Medicina do ABC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo Andre</city>
        <state>Sao Paulo</state>
        <zip>09060-870</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo André</city>
        <state>São Paulo</state>
        <zip>09060-870</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2011</study_first_submitted>
  <study_first_submitted_qc>January 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <last_update_submitted>January 29, 2012</last_update_submitted>
  <last_update_submitted_qc>January 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Faculdade de Medicina do ABC</investigator_affiliation>
    <investigator_full_name>Felipe Melo Cruz</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>oxaliplatin</keyword>
  <keyword>vitamin e</keyword>
  <keyword>neuropathy</keyword>
  <keyword>peripheral</keyword>
  <keyword>prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 18, 2014</submitted>
    <returned>March 3, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

